DRRX Stock Price History and Quote Analysis Insights for Investors
DURECT Corporation
Stock Price Today
DURECT Corporation (DRRX) stock declined over -2.73%, trading at $0.78 on NASDAQ, down from the previous close of $0.80. The stock opened at $0.79, fluctuating between $0.76 and $0.81 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Company Information
| Employees | 48 |
| Beta | 1.13 |
| Sales or Revenue | $8.55M |
| 5Y Sales Change% | -0.722% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Frequently Asked Questions
DURECT Corporation (NASDAQ: DRRX) stock price is $0.78 in the last trading session. During the trading session, DRRX stock reached the peak price of $0.81 while $0.76 was the lowest point it dropped to. The percentage change in DRRX stock occurred in the recent session was -2.73% while the dollar amount for the price change in DRRX stock was -$0.02.
The NASDAQ listed DRRX is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. DURECT Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Andrew R. Miksztal Ph.D.
Vice President of Pharmaceutical R&D and Principal Scientist
Dr. Norman L. Sussman M.D.
Chief Medical Officer
Ms. Judy R. Joice
Senior Vice President of Operations & Corporation Quality Assurance
Dr. Su Il Yum Ph.D.
Executive Officer
Mr. Timothy M. Papp M.B.A.
Chief Financial Officer & Sec.
Ms. Jian Li M.B.A.
Interim Principal Accounting Officer, Senior Vice President of Fin., Corporation Controller & Sec.
Dr. James E. Brown D.V.M.
Co-Founder, Chief Executive Officer, Pres & Director
Dr. WeiQi Lin M.D., Ph.D.
Executive Vice President of R&D and Principal Scientist
Mr. Steve Helmer J.D.
Vice President & Chief Patent Counsel
Mr. Keith L. Lui M.B.A.
Senior Vice President of Bus. Devel., Commercial & Medical Affairs
DRRX's closing price is 61.88% higher than its 52-week low of $0.48 where as its distance from 52-week high of $1.88 is -58.67%.
Number of DRRX employees currently stands at 48.
Official Website of DRRX is: https://www.durect.com
DRRX could be contacted at phone 408 777 1417 and can also be accessed through its website. DRRX operates from 10260 Bubb Road, Cupertino, CA 95014-4166, United States.
DRRX stock volume for the day was 58.47K shares. The average number of DRRX shares traded daily for last 3 months was 78.32K.
The market value of DRRX currently stands at $24.12M with its latest stock price at $0.78 and 31.04M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com